Skip to main content
Signal8

Hepion Pharmaceuticals, Inc. (HEPA)

Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

OTC:HEPAHealthcare
+13.64%$0.1150
CLOSED
Mkt Cap$14.17M
EV-
Float11.42M
O/S123.22M
VOL33K sh
$ Vol$4K
RVOL0.86×
Inst Own0.0%
Net Cash/Sh-
Dilution
Hepion Pharmaceuticals, Inc. logoOTC:HEPAClosed$0.1150+13.64%

Hepion Pharmaceuticals, Inc. (HEPA) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 53 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
7 warrant series recorded as outstanding
Most recent offering
PIPE, closed Sep 3, 2026
Source: 8-K filed Sep 8, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro